AUS
NZ
UK
CA
USA
IND
Highlights
- The combination of evorpacept with rituximab and lenalidomide achieved complete responses in 92% of untreated indolent non-Hodgkin lymphoma patients, well above the historically observed rate of around 50% for R2 alone.
- The study showed the regimen was well tolerated in the frontline setting, delivering robust anti-tumor activity without chemotherapy.
- Ongoing evaluation will determine the regimen’s effect on minimal residual disease (MRD) eradication as longer-term data matures.
ALX Oncology Holdings Inc. (Nasdaq:ALXO) disclosed encouraging interim findings from a Phase 2 investigator-sponsored study evaluating evorpacept combined with the standard treatment regimen of rituximab and lenalidomide (R2) in patients with untreated indolent B-cell non-Hodgkin lymphoma (iNHL). These results were shared on December 7, 2025, at the American Society of Hematology (ASH) Annual Meeting in Orlando, demonstrating a significant improvement in treatment response rates compared to historical data for R2 alone.
Breakthrough Response Rates in Frontline Treatment
In this Phase 2 trial led by Dr. Paolo Strati from The University of Texas MD Anderson Cancer Center, 24 patients with untreated indolent B-cell non-Hodgkin lymphoma were enrolled, including 14 with follicular lymphoma and 10 with marginal zone lymphoma. The study's primary goal was to exceed an 80% complete response rate by adding evorpacept to the standard R2 regimen.
The results surpassed expectations, with 22 patients (92%) achieving complete response (CR), while the remaining 8% reached partial response (PR), making the overall response rate (ORR) 100%. These figures compare favorably against the approximately 50% CR rate typically seen with R2 therapy alone, marking a notable improvement for therapy-naïve patients.
Safety and Tolerability Profile
The combination treatment was generally well tolerated, showing no unexpected safety issues. Importantly, this regimen avoids chemotherapy, offering a less toxic frontline option. These features may help improve patient quality of life and treatment adherence.
One-year progression-free survival (PFS) was reported at 91%, with an overall survival (OS) rate reaching 100%, underscoring the durability of clinical benefits observed with evorpacept plus R2.
Next Steps in Clinical Evaluation
The research team plans to continue monitoring patients to assess the minimal residual disease (MRD) eradication rate, which will provide further insights into the depth of response and potential long-term disease control. These ongoing evaluations will help define evorpacept’s role in frontline iNHL treatment.
The ASH 2025 poster presentation detailing this study was available for viewing with Dr. Strati presenting findings during the session on indolent B-cell lymphomas.
About ALX Oncology
ALX Oncology is a clinical-stage biotech company developing new cancer therapies aimed at improving patient outcomes. Its lead candidate, evorpacept, is being tested in multiple cancer types. Additionally, ALX Oncology has advanced ALX2004, an EGFR-targeted antibody-drug conjugate, to Phase 1 clinical trials as of August 2025.
